(CercleFinance.com) – BVF Partners LP, acting on behalf of the funds it manages, declared to the AMF that it crossed downwards, on December 23, the thresholds of 10% of the capital and voting rights of ‘Erytech Pharma, as a result of a sale of shares on the market.
The declarant specified that he held, on behalf of said funds, 2,299,301 Erytech shares representing as many voting rights, i.e. 7.41% of the capital and 7.07% of the voting rights of this clinical-stage biopharmaceutical company.